首页> 外国专利> METHOD FOR PREDICTION OF CLINICAL COURSE OF DIFFUSE LIVER DISEASES

METHOD FOR PREDICTION OF CLINICAL COURSE OF DIFFUSE LIVER DISEASES

机译:弥漫性肝病临床过程的预测方法

摘要

FIELD: medicine.;SUBSTANCE: invention refers to medicine, namely to ultrasonic diagnostics, and can be used for prediction of clinical course of diffuse liver diseases. Contrast-enhanced ultrasound investigation (CEUSI) of the liver is performed to assess quantitative parameters of contrasting. Phases of contrasting are assessed by zones 5 and 6 with subsequent analysis of the beginning of the arterial phase, the maximum intensity of accumulation of the contrast preparation and time of 50 % excretion of the contrast preparation with calculation of the differences in zones 5 and 6. At that, zones 5 and 6 define the operator himself so that zone 5 is a hepatic tissue segment located between the middle and right hepatic veins, and zone 6 is three sections of hepatic tissue located at equal distance from each other along periphery of right lobe of liver. Zone 5 is located in proximal direction to the liver gates, and zone 6 is distal to the liver gates. Zones 5 and 6 include: homogeneous hepatic tissue, vessels, bile ducts, wherein the liver capsule is not included. After the contrast agent is administered, continuous ultrasound monitoring and video recording of contrast enhancement are performed. At the end of the examination, the catheter through which the contrast preparation was introduced is removed and the analyzed ultrasonic image is analyzed for all phases of contrasting. Zones 5 and 6 are selected on video loops. Then, for zones 5 and 6, time of beginning of arterial phase, maximum intensity of accumulation of contrast agent, time of 50 % excretion of contrast agent are determined. For zone 6 values of each parameter are summed and divided by 3 with calculation of average values. Difference between the indicators of zones 5 and 6 is determined. If arterial phase onset in zone 6 is increased by 15 % and more as compared to zone 5, as well as 15 % decrease or more of the maximum intensity of contrasting in zone 6 compared to zone 5 and the time increase of 50 % of the contrast increase by 20 % and more in zone 6 compared to zone 5, the unfavorable clinical course of the diffuse liver diseases is predicted. If the difference is less than 15 % of the beginning of the arterial phase and the maximum intensity of contrasting, as well as less than 20 % of the time difference of 50 % of the contrast preparation, the prognosis is considered favorable.;EFFECT: method provides eliminating invasiveness, reducing time for evaluating the progression of diffuse hepatic diseases, as well as the possibility of dynamic observation of the clinical course of the disease by using CEUSI.;1 cl, 2 dwg, 1 ex
机译:技术领域本发明涉及医学,即超声诊断学,可用于预测弥漫性肝病的临床过程。进行肝脏超声造影检查(CEUSI)以评估造影定量参数。通过区域5和6评估对比阶段,随后分析动脉开始阶段,对比制剂的最大累积强度和对比制剂排泄50%的时间,并计算区域5和6的差异那时,区域5和6定义了操作员本人,因此区域5是位于肝中静脉和右肝静脉之间的肝组织段,区域6是沿右边缘彼此等距分布的三个肝组织部分肝叶。区域5位于肝门附近,区域6位于肝门远侧。区域5和6包括:均质的肝组织,血管,胆管,其中不包括肝囊。在施用造影剂之后,进行连续的超声监测和造影剂增强的视频记录。在检查结束时,取出引入造影剂的导管,并分析分析的超声图像的所有造影阶段。在视频循环上选择区域5和6。然后,对于区域5和6,确定动脉开始阶段的时间,造影剂积累的最大强度,造影剂排泄50%的时间。对于区域6,将每个参数的值相加并除以3,然后计算平均值。确定区域5和6的指示器之间的差异。如果区域6中的动脉相位发作比区域5增大了15%以上,并且与区域5相比区域6的最大对比强度下降了15%或更多,并且时间增加了50%与区域5相比,区域6的对比度增加了20%甚至更多,因此可预测弥漫性肝病的临床病程不利。如果差异小于动脉期开始时的15%和最大对比强度,并且小于对比剂的50%时差的20%,则预后良好。该方法可消除侵袭性,减少评估弥漫性肝病进展的时间,并可以通过使用CEUSI动态观察该疾病的临床过程。1cl,2 dwg,1 ex

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号